Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 3:01 AM
Ignite Modification Date: 2025-12-25 @ 3:01 AM
NCT ID: NCT04953533
Eligibility Criteria: gout Inclusion Criteria: 1. age:year of 25\~60; 2. Be consistent with the 2015 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) gout diagnostic criteria ,and serum uric acid \>420 μmol/L; 3. The patient are willing to take part in our study. Exclusion Criteria: 1. abronia, surgery, postoperative, dehydration within 2 weeks, acute or chronic infectious diseases, severe trauma, malnutrition, diabetes, malignant tumors; 2. diagnosed as cardiovascular and cerebrovascular diseases within 3 months; 3. heart failure (New York Heart Academy,grade IV); 4. hepatic insufficiency ( Alanine transaminase or Aspartate aminotransferase ≥3×upper limit); 5. chronic kidney disease or abnormal renal function( serum creatinine ≥1.5×upper limit); 6. excessive drinking; 7. The investigators considered the patients unsuitable for inclusion in this study. hyperuricemia: Inclusion Criteria: 1. age:year of 25\~60; 2. A medical record in our hospital showed that the person is healthy, without key disease; 3. serum uric acid \>420μmol/L without gout flares. Exclusion Criteria:Same as the group of gout. healthy controls: Inclusion Criteria: age:year of 25\~60; A medical record in our hospital showed that the person is healthy, without key disease; serum uric acid ≤420μmol/L. Exclusion Criteria:Same as the group of gout.
Healthy Volunteers: True
Sex: MALE
Minimum Age: 25 Years
Maximum Age: 60 Years
Study: NCT04953533
Study Brief:
Protocol Section: NCT04953533